Trimel Announces Exclusive License Agreement With Endo for NATESTO(TM)
Conference Call Scheduled for 8:30 a.m. EST on Monday, November 24th, 2014
(firmenpresse) - TORONTO, ONTARIO -- (Marketwired) -- 11/24/14 -- Trimel Pharmaceuticals Corporation (TSX: TRL) today announced the signing of an agreement by its subsidiary, Trimel Biopharma SRL, providing an affiliate of Endo International plc (NASDAQ: ENDP) (TSX: ENL) with the exclusive rights to market NATESTO™ in the United States and Mexico. NATESTO™ is the first and only FDA-approved testosterone nasal gel indicated for replacement therapy in adult males diagnosed with hypogonadism.
Under the terms of the agreement, Trimel is eligible to receive payments of up to US$165 million based on certain regulatory and sales milestones in addition to an upfront fee of US$25 million and a prepaid inventory deposit of US$5 million upon closing of the deal. Additionally, Trimel will be responsible for the manufacture of NATESTO™ and receive a tiered supply price for the product. Closing of the transaction is subject to customary Hart-Scott-Rodino approval.
"We are delighted to announce this partnership agreement with Endo as it represents another significant achievement for our company and an opportunity to capture the value we have created in developing NATESTO™," said Tom Rossi, President and CEO of Trimel. "Endo is a leader in the U.S. men's health care and urology segments, making them the ideal partner for NATESTO™. We look forward to working with Endo as they prepare to launch this innovative and differentiated treatment option for patients suffering from low testosterone."
Conference Call
Trimel management will host a conference call to discuss the transaction on Monday, November 24, 2014 at 8:30 a.m. Eastern Standard Time. Following the discussion, Trimel executives will address inquiries from investment analysts.
To access the call live, please dial 416-340-8530 or 1-800-952-6845. Listeners are encouraged to dial in 10 minutes before the call begins to avoid delays.
A replay of the conference call will be available until 7:00 p.m. Eastern Standard Time on Monday, December 1, 2014 by dialing 905-694-9451 or 1-800-408-3053, using access code: 3080803#.
About NATESTO™ (testosterone) Nasal Gel
Indications and Usage
NATESTO™ is an androgen indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone including:
Limitations of Use
Safety and efficacy of NATESTO™ in males less than 18 years old have not been established.
Dosage
NATESTO™ for intranasal use is available as a metered-dose pump. One pump actuation delivers 5.5 mg of testosterone. The recommended dose of NATESTO™ is 11 mg of testosterone (two pump actuations, one per nostril), applied intranasally three times daily for a total daily dose of 33 mg.
Contraindications
Warnings and Precautions
Adverse Reactions
The most common adverse reactions (incidence greater than or equal to3%) to NATESTO™ observed in clinical trials were an increase in prostate specific antigen (PSA), headache, rhinorrhea, epistaxis, nasal discomfort, nasopharyngitis, bronchitis, upper respiratory tract infection, sinusitis and nasal scab.
About Trimel
Trimel is a specialty pharmaceutical company involved in the sale, distribution, and development of products with a focus in men's health, women's health, and respiratory medicine. NATESTO™, a product utilizing Trimel's licensed nasal gel technology, has been approved for sale in the United States by the FDA and is licensed to an affiliate of Endo International plc for commercialization. For more information, please visit .
About Endo
Endo International plc is a global specialty healthcare company focused on improving patients' lives while creating shareholder value. Endo develops, manufactures, markets, and distributes quality branded pharmaceutical, generic and device products through its operating companies. Endo has global headquarters in Dublin, Ireland, and US headquarters in Malvern, PA. Learn more at .
Notice regarding forward-looking statements:
Information in this press release that is not current or historical factual information may constitute forward looking information within the meaning of securities laws. Implicit in this information are assumptions regarding our future operational results. These assumptions, although considered reasonable by the company at the time of preparation, may prove to be incorrect. Readers are cautioned that actual performance of the company is subject to a number of risks and uncertainties, including with respect to the performance of NATESTO™ and could differ materially from what is currently expected as set out above. For more exhaustive information on these risks and uncertainties you should refer to our annual information form dated March 5, 2014 which is available at . Forward-looking information contained in this press release is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. You should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any particular time, whether as a result of new information, future events or otherwise, except as required by applicable securities law.
Contacts:
Contact: Kenneth G. Howling
Chief Financial Officer
(416) 679-0536
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 24.11.2014 - 12:00 Uhr
Sprache: Deutsch
News-ID 354872
Anzahl Zeichen: 0
contact information:
Town:
TORONTO, ONTARIO
Kategorie:
Healthcare
Diese Pressemitteilung wurde bisher 253 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Trimel Announces Exclusive License Agreement With Endo for NATESTO(TM)"
steht unter der journalistisch-redaktionellen Verantwortung von
Trimel Pharmaceuticals Corporation (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
